Health Care Systems
Health care systems organise the finance and delivery of health care. They vary by country, reflecting specific history, culture, and economics. To maximise coverage and efficiency they must evolve with changing demographics, needs, and technologies.
Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE
1 July 2026
Abu Dhabi is taking important steps to strengthen the use of HTA in healthcare decision-making, with the publication of its HTA guidelines in 2025 marking an important milestone.
Can HTA keep up with innovation?
23 June 2026
But the pace of innovation often outruns policy – new developments in innovative therapies, digital health technologies, and a shifting geopolitical landscape are pushing HTA systems…
Cost-effectiveness thresholds: theory, pragmatism, and NICE’s new number
16 June 2026
Grace Hampson is joined by Adrian Towse, who ran OHE as its Director for many years, and Chris Sampson, Senior Principal Economist at OHE, to dig into one…
Most Favored Nation pricing: what it means for policy, patients and pharma
5 May 2026
US pharmaceutical prices are the highest in the world – President Trump’s Most Favoured Nation (MFN) policy is trying to change that. But what does MFN pricing mean in practice?
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with millions of cases and high mortality each year. Patients with bloodstream…
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible for substantial health and economic burden to health systems and wider society.
Europe’s pharmaceutical policy choices – And what the United States stands to learn
18 March 2026
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw from Europe’s experience with pharmaceutical pricing and innovation. As a participant, my key takeaways focused on understanding the trade-offs underpinning EU and UK drug pricing policy and the broader impact on innovation for both sides of the Atlantic.
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
25 February 2026
NICE’s cost-effectiveness threshold will rise in April 2026, for the first time in 20 years. This raises important questions to consider as we approach the change and in the years that follow.